CAR-mediated induction of enzymes can lead to significant drug-drug interactions (DDIs). By increasing the metabolism of co-administered drugs, CAR activation can reduce their therapeutic efficacy or, conversely, increase the production of toxic metabolites. Understanding the role of CAR in DDIs is crucial for predicting and managing potential adverse effects during polypharmacy.
